Haemonetics
246 hedge funds and large institutions have $3.12B invested in Haemonetics in 2017 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 75 increasing their positions, 87 reducing their positions, and 19 closing their positions.
205% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 19
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more capital invested
Capital invested by funds: $2.46B → $3.12B (+$657M)
19% more funds holding
Funds holding: 207 → 246 (+39)
2.61% less ownership
Funds ownership: 104.14% → 101.53% (-2.6%)
14% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 87
37% less call options, than puts
Call options by funds: $889K | Put options by funds: $1.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$46.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.1M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$18.6M |
| 4 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
+$15M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$56.9M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$56.8M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$33.8M |
| 4 |
HIM
Hermes Investment Management
London Uk,
United Kingdom
|
-$30M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$29.9M |
HAE Hedge Fund Activity: Q4 2017 in Review
246 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2017, worth a combined $3.12B — up 27% from $2.46B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new HAE positions and 19 closed out — a net gain of 39 holders — while 75 added to existing stakes and 87 trimmed.
The largest buyer was AJO LP, opening a new position worth an estimated $46.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $56.9M.
- 246 institutional investors held Haemonetics (HAE) as of Q4 2017, up from 207 in Q3 2017.
- Funds reported $3.12B of Haemonetics stock for Q4 2017, up 27% quarter-over-quarter.
- 58 funds opened new Haemonetics positions in Q4 2017 and 19 closed out, a net change of +39 holders.
- The largest Haemonetics buyer in Q4 2017 was AJO LP, an estimated $46.5M added.
- The largest Haemonetics seller in Q4 2017 was T. Rowe Price Associates, an estimated $56.9M sold.
Based on aggregated 13F filings for Q4 2017.